United Kingdom · Question · Written question
UIN 3107
Trastuzumab Deruxtecan
Original
Introduced
30 August 2024
Last action
9 September 2024 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
9 September 2024
Summary
To ask the Secretary of State for Health and Social Care, if he will make representations to (a) Daiichi Sankyo and (b) AstraZeneca following the decision by NICE not to recommend Enhertu as a cost effective treatment for advanced stage breast cancer.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
30 August 2024
Written question
To ask the Secretary of State for Health and Social Care, if he will make representations to (a) Daiichi Sankyo and (b) AstraZeneca following the decision by NICE not to recommend Enhertu as a cost effective treatment for advanced stage breast cancer.
Source: Commons
9 September 2024
Answer
Decisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE), on the basis of an evaluation of a treatment’s costs and benefits. The NICE’...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2024-08-30/3107
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1725847
- uk · wq-1725847 · source updated 9 September 2024